Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine

BACKGROUND: Currently licensed human vaccines are subtype-specific and do not protect against pandemic H5N1 viruses. Previously, our group has reported on the construction of an influenza virus-like particle (VLP) as a new generation candidate vaccine. A mixture of influenza H5N1 VLPs representing c...

Descripción completa

Detalles Bibliográficos
Autores principales: Crevar, Corey J, Ross, Ted M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583969/
https://www.ncbi.nlm.nih.gov/pubmed/18957098
http://dx.doi.org/10.1186/1743-422X-5-131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583969/
https://www.ncbi.nlm.nih.gov/pubmed/18957098
http://dx.doi.org/10.1186/1743-422X-5-131

Ejemplares similares